At a glance
ClinicalIndex Comparison RecordN/ACompleted· 298 enrolled
Drug / intervention
ferric carboxymaltose +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open, Prospective, Randomized Study on the Efficacy of Iron Therapy Using Intravenous (IV) Iron Supplements Relative to Oral Iron Intake for Increasing Left Ventricular Systolic Function in Patients With Myocardial Infarction
In Brief
A clinical study evaluating ferric carboxymaltose and ferrous sulphate for Myocardial Infarction and Iron-deficiency. Completed, enrolled 298 participants across 1 site.
Detailed Summary
The OPERA-MI trial evaluates the effect of i.v. ferric carboxymaltose compared to the effect of oral iron, on left ventricular systolic function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Iron-deficiency
CountriesRussia
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartDec 2021
First PostedApr 2022
Primary CompletionSep 2025
TodayJul 2026
First PostedApr 4, 2022
Enrollment StartDec 5, 2021
Primary CompletionSep 15, 2025
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 4.2 years ago
Interventions
ferric carboxymaltosedrug
ferric carboxymaltose is i.v. iron, 99 patiants will be randomised to this group
ferrous sulphatedrug
ferrous sulphate is oral iron, 100 patiants will be randomised to this group